CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Benefits of Outsourcing Regulatory Compliance Services for Chemical Formulations

Benefits of Outsourcing Regulatory...

Key Regulatory Compliance Challenges Facing Life Science Organizations

Key Regulatory Compliance Challenges...

Advarra Offers Cloud-Based Secure Document Exchange To Boost Startup

Advarra Offers Cloud-Based Secure...

Criterion Edge Named Company Of The Year By Life Sciences Review

Criterion Edge Named Company Of The...

Life Sciences Must Prioritize Business Validation

Life Sciences Must Prioritize...

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to...

Is 2022 the Developmental Phase of Life Sciences?

Is 2022 the Developmental Phase of...

Life Science Compliance Through Learning And Development

Life Science Compliance Through...

Benefits of Outsourcing Regulatory Compliance Services for Chemical Formulations

Benefits of Outsourcing Regulatory...

Key Regulatory Compliance Challenges Facing Life Science Organizations

Key Regulatory Compliance Challenges...

Advarra Offers Cloud-Based Secure Document Exchange To Boost Startup

Advarra Offers Cloud-Based Secure...

Criterion Edge Named Company Of The Year By Life Sciences Review

Criterion Edge Named Company Of The...

Life Sciences Must Prioritize Business Validation

Life Sciences Must Prioritize...

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to...

Is 2022 the Developmental Phase of Life Sciences?

Is 2022 the Developmental Phase of...

Life Science Compliance Through Learning And Development

Life Science Compliance Through...

Lithuania's Vision to Become a Biotech Hub in Europe

Life Sciences Review | Tuesday, June 07, 2022
Tweet

Ahead of the BIO conference, Innovation Agency, Lithuania explains what the country’s plans are for future growth in the area and how this is built upon students heading into STEM studies.


FREMONT, CA: The Baltic nation has set a goal of having life sciences account for five per cent of its GDP by 2030, which is likely to represent a five-fold increase from the time of the declaration. The country representing diverse business sectors, Innovation Agency Lithuania, stated ahead of the BIO International Conference that the country is eager to expand its ties with the business in the United States, which accounted for 28 per cent of its life sciences exports in 2021. Northway Biotech, a Lithuanian contract development and manufacturing company, recently strengthened the connection by establishing a manufacturing facility in Boston, Massachusetts.


Lithuania’s emphasis on science has proved beneficial in terms of the number of students who choose to study STEM topics, with 25 per cent of students preferring to study those subjects. Another advantage for Lithuania is that, despite the industry's overall push for inclusion and 


diversity, 58 per cent of researchers in the country are women. The Innovation Agency Lithuania seeks to be an entrance point for global enterprises to connect with partners in Lithuania as well as provide financial support to 'innovation projects' of all kinds of organisations. One of the agency's responsibilities at BIO is to enable Lithuanian enterprises to interact with partners, and the country will be represented by eight life sciences companies, one of which is Biomapas, a contract research organisation (CRO).


Biomapas specialises in delivering regulatory, clinical, and pharmacovigilance services to biological product companies. Its services can help assets proceed from the preclinical stage through Phase III trials. On an enquiry about the company’s work, Biomapas chief global clinical research officer stated that the entire clinical research team concentrates on early phase clinical trial delivery, thus uniting the medication developer, the investigation’s site and the patients. The company also owns BIO1, a specialised early-phase clinical trial site housed inside a large university hospital with access to all of the necessary information and equipment to identify patients who are suited for clinical trials and ensure their safety.


Weekly Brief

loading
Top 10 Regulatory Services Companies – 2023
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Value of New Antibiotics in the Fight Against AMR

Piero Rijli, Corporate Director, Regulatory Activities and Market Access, MENARINI Group

Improving Minimal Residual Disease Detection Using NGS

Steven Henck, Ph.D., Vice President of R&D, Integrated DNA Technologies

Multiomic Preclinical Models to Define the Mechanism of Action

Mitch Sanders, Chief Scientific Officer and EVP of the ProDevLab, at Alira Health

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Sanjay Konagurthu, Senior Director, PDS Global Science and Technology, Thermo Fisher Scientific

What the New EMA Draft "Guideline on Computerised Systems and Electronic Data" Means to Your Systems

Cathlin Shapiro, Director, Technology Quality Assurance, Parexel

Pharmaceutical Tablet Coating - Past, Present and Future

Steve Brown, Senior Director EU and APAC Global Manufacturing Science and Technology, Teva Pharmaceuticals [NYSE: TEVA]

Dynamic Commercial Aspects of Life Sciences

Jim Cooper, Director, Clinical Operations, Moderna

Achieving trial master file quality, timeliness and completeness

Susan K. Maue, Designation : Managing Director PharmaLex
Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/lithuania-s-vision-to-become-a-biotech-hub-in-europe-nwid-841.html